Maxcyte (MXCT) Gains from Investment Securities (2020 - 2021)

Maxcyte's (MXCT) quarterly Gains from Investment Securities came in at $287200.0 in Q3 2021, up 2688.35% on a QoQ basis from $10300.0 in Q2 2021.

Maxcyte (MXCT) Gains from Investment Securities (2020 - 2021) Analysis & Trends

Maxcyte (MXCT) has 2 years of Gains from Investment Securities data on file, last reported at $287200.0 in Q3 2021.

On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $287200.0 in Q3 2021; TTM through Dec 2021 was $645400.0, a N/A change from a year earlier, with the FY2021 full-year figure at $645400.0, up 76.1% from the prior year.
Gains from Investment Securities for Q3 2021 stood at $287200.0, up from $10300.0 in the prior quarter.
Over the last five years, Gains from Investment Securities for MXCT reached as high as $347900.0 in Q1 2021 and fell as low as $10300.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	182.35 Bn	175.06 Bn	6.27 Bn
2	Stryker	128.79 Bn	125.91 Bn	3.81 Bn
3	Medtronic	107.93 Bn	98.71 Bn	6.41 Bn
4	Boston Scientific	67.82 Bn	66.37 Bn	3.61 Bn
5	Edwards Lifesciences	48.03 Bn	44.36 Bn	1.29 Bn
6	Dexcom	28.30 Bn	27.18 Bn	750.30 Mn
7	GE HealthCare Technologies	27.90 Bn	25.62 Bn	1.98 Bn
8	Smith & Nephew	27.01 Bn	26.43 Bn	-
9	Koninklijke Philips	23.96 Bn	20.83 Bn	2.07 Bn
10	Maxcyte	111.68 Mn	111.68 Mn	8.08 Mn

Download Data